Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Filip Scheperjans"'
Autor:
Ilhan Cem Duru, Alexandre Lecomte, Tânia Keiko Shishido, Pia Laine, Joni Suppula, Lars Paulin, Filip Scheperjans, Pedro A. B. Pereira, Petri Auvinen
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract The human gut microbiome composition has been linked to Parkinson’s disease (PD). However, knowledge of the gut microbiota on the genome level is still limited. Here we performed deep metagenomic sequencing and binning to build metagenome-
Externí odkaz:
https://doaj.org/article/5de8b9a999d7419bb1cbd8c6072ff9b6
Autor:
Sebastian Heinzel, Jenna Jureczek, Veera Kainulainen, Anni I. Nieminen, Ulrike Suenkel, Anna-Katharina von Thaler, Christoph Kaleta, Gerhard W. Eschweiler, Kathrin Brockmann, Velma T. E. Aho, Petri Auvinen, Walter Maetzler, Daniela Berg, Filip Scheperjans
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Fecal calprotectin is an established marker of gut inflammation in inflammatory bowel disease (IBD). Elevated levels of fecal calprotectin as well as gut microbial dysbiosis have also been observed in other clinical conditions. However, syst
Externí odkaz:
https://doaj.org/article/a46199f195e744deaee36af9c329bc9e
Autor:
Jeffrey M. Boertien, Kirsi Murtomäki, Pedro A. B. Pereira, Sygrid van der Zee, Tuomas H. Mertsalmi, Reeta Levo, Tanja Nojonen, Elina Mäkinen, Elina Jaakkola, Pia Laine, Lars Paulin, Eero Pekkonen, Valtteri Kaasinen, Petri Auvinen, Filip Scheperjans, Teus van Laar, PPNN Study Group
Publikováno v:
npj Parkinson's Disease, Vol 8, Iss 1, Pp 1-12 (2022)
Abstract Gut microbiota alterations in Parkinson’s disease (PD) have been found in several studies and are suggested to contribute to the pathogenesis of PD. However, previous results could not be adequately adjusted for a potential confounding eff
Externí odkaz:
https://doaj.org/article/8190dbfd723046688afdf55eea320d34
Autor:
Kirsi Murtomäki, Juho Joutsa, Tuomas Mertsalmi, Elina Jaakkola, Elina Mäkinen, Reeta Levo, Mikael Eklund, Simo Nuuttila, Eero Pekkonen, Tommi Noponen, Toni Ihalainen, Valtteri Kaasinen, Filip Scheperjans
Publikováno v:
Brain and Behavior, Vol 13, Iss 7, Pp n/a-n/a (2023)
Abstract Background Gastrointestinal symptoms are common in Parkinson's disease (PD), but their neurophysiological correlates are not well understood. We recently reported that functional gastrointestinal symptoms were not associated with asymmetry p
Externí odkaz:
https://doaj.org/article/4e9997aad2ec4a8f9f0a7e59a537f689
Autor:
Berta Bosch, Anna Hartikainen, Aki Ronkainen, Filip Scheperjans, Perttu Arkkila, Reetta Satokari
Publikováno v:
Microorganisms, Vol 11, Iss 12, p 2901 (2023)
Fecal microbiota transplantation (FMT) has shown highly variable results in indications beyond recurrent Clostridioides difficile infection. Microbiota dysbiosis in many diseases is characterized by the depletion of strictly anaerobic bacteria, which
Externí odkaz:
https://doaj.org/article/f7787c208fb3426eb7801e82ab09e480
Autor:
Sammeli Liikkanen, Janne Sinkkonen, Joni Suorsa, Valtteri Kaasinen, Eero Pekkonen, Mikko Kärppä, Filip Scheperjans, Teppo Huttunen, Toni Sarapohja, Ullamari Pesonen, Mikko Kuoppamäki, Tapani Keränen
Publikováno v:
PLOS Digital Health, Vol 2, Iss 4, p e0000225 (2023)
In the quantification of symptoms of Parkinson's disease (PD), healthcare professional assessments, patient reported outcomes (PRO), and medical device grade wearables are currently used. Recently, also commercially available smartphones and wearable
Externí odkaz:
https://doaj.org/article/012d6c5856004986a94efd8d4883e5a0
Autor:
Pedro A. B. Pereira, Drupad K. Trivedi, Justin Silverman, Ilhan Cem Duru, Lars Paulin, Petri Auvinen, Filip Scheperjans
Publikováno v:
npj Parkinson's Disease, Vol 8, Iss 1, Pp 1-17 (2022)
Abstract We aimed to investigate the link between serum metabolites, gut bacterial community composition, and clinical variables in Parkinson’s disease (PD) and healthy control subjects (HC). A total of 124 subjects were part of the study (63 PD pa
Externí odkaz:
https://doaj.org/article/f140344979fd47ddbf19c1cd4cbae81c
Autor:
Valtteri Räty, Mikael Eklund, Simo Nuuttila, Elina Jaakkola, Elina Mäkinen, Kirsi Murtomäki, Tanja Nojonen, Reeta Levo, Tuomas Mertsalmi, Juho Joutsa, Filip Scheperjans, Valtteri Kaasinen
Publikováno v:
Clinical Parkinsonism & Related Disorders, Vol 8, Iss , Pp 100184- (2023)
Diagnostic usefulness of the floating door sign was tested in 144 PD patients, 41 essential tremor patients and 38 controls. There were no differences in the presence of floating door sign between PD and ET patients. The sign does not seem to be a re
Externí odkaz:
https://doaj.org/article/9a80f73f33b0461ea85fddeaf7d497d7
Publikováno v:
npj Parkinson's Disease, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract Gut microbiota influences the clinical response of a wide variety of orally administered drugs. However, the underlying mechanisms through which drug–microbiota interactions occur are still obscure. Previously, we reported that tyrosine de
Externí odkaz:
https://doaj.org/article/0e431291b2654d0aa0852d1e827ffd3c
Autor:
Velma T. E. Aho, Madelyn C. Houser, Pedro A. B. Pereira, Jianjun Chang, Knut Rudi, Lars Paulin, Vicki Hertzberg, Petri Auvinen, Malú G. Tansey, Filip Scheperjans
Publikováno v:
Molecular Neurodegeneration, Vol 16, Iss 1, Pp 1-14 (2021)
Abstract Background Previous studies have reported that gut microbiota, permeability, short-chain fatty acids (SCFAs), and inflammation are altered in Parkinson’s disease (PD), but how these factors are linked and how they contribute to disease pro
Externí odkaz:
https://doaj.org/article/62e11fcfd73d4e62812cf8a1ab31083e